Market Intelligence, Clinical Progress, and High-Purity Reagents for Proteasome-Targeted Oncology and Antiviral Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PSMA7 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PSMA7 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View PSMA7 Products |
| Gene Delivery | PSMA7 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View PSMA7 Products |
| Benchmark Ab | Anti-PSMA7 Recombinant Antibody Recombinant positive control for assay validation. |
View PSMA7 Products |
| Validator | PSMA7 siRNA Set For knockdown verification. |
View PSMA7 Products |
| Related Target A | PSMB5 Primary catalytic core of the proteasome; key to assessing resistance bypass. |
View PSMB5 Products |
| Related Target B | PSMD14 Proteasome-associated deubiquitinase; synergistic target in protein degradation pathways. |
View PSMD14 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Screening for protein-protein interaction (PPI) inhibitors | Recombinant PSMA7 proteins with strictly verified theoretical MW and high purity (>95%) to prevent non-specific binding. |
| Subfamily counter screening (PSMA1-PSMA6) | Homolog panel proteins strictly verified by mass spectrometry and sequence analysis to ensure assay specificity. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live PSMA7 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PSMA7 therapeutics is intensifying, with major players shifting focus from traditional proteasome catalytic inhibitors to protein-protein interaction (PPI) disruptors and targeted protein degraders (PROTACs). As first-generation therapies reach the clinic, the next wave of R&D is targeting the specific regulatory subunits of the 20S proteasome core to bypass systemic toxicity and acquired drug resistance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI) | Academic Institutes, Biotech Startups | Colorectal Cancer, Glioblastoma | Selectivity Assay (Need Mutant vs WT Proteins) |
| PROTAC / Degrader | Arvinas, Kymera Therapeutics (Inferred) | Solid Tumors, Hematological Malignancies | Target Validation (Need Lentivirus for Stable Cell Lines) |
| siRNA Therapeutics | Alnylam, Arrowhead (Exploratory) | Viral Infections (HBV, HCV) | Knockdown Validation (Need high-purity siRNA and qPCR controls) |